EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Duchenne muscular dystrophy: disease mechanism and therapeutic strategies

Addeli Bez Batti Angulski, Nora Hosny, Houda Cohen, Ashley A Martin, Dongwoo Hahn, Jack Bauer, Joseph M Metzger

Frontiers in Physiology · 26.06.2023 · 14

DOI: 10.3389/fphys.2023.1183101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Physiology, online erschienen am 26.06.2023. Verfasst von Addeli Bez Batti Angulski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, MN, United States. Die Arbeit wurde bisher 176-mal zitiert (Crossref) und nennt 430 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a severe, progressive, and ultimately fatal disease of skeletal muscle wasting, respiratory insufficiency, and cardiomyopathy. The identification of the dystrophin gene as central to DMD pathogenesis has led to the understanding of the muscle membrane and the proteins involved in membrane stability as the focal point of the disease. The lessons learned from decades of research in human genetics, biochemistry, and physiology have culminated in establishing the myriad functionalities of dystrophin in striated muscle biology. Here, we review the pathophysiological basis of DMD and discuss recent progress toward the development of therapeutic strategies for DMD that are currently close to or are in human clinical trials. The first section of the review focuses on DMD and the mechanisms contributing to membrane instability, inflammation, and fibrosis. The second section discusses therapeutic strategies currently used to treat DMD. This includes a focus on outlining the strengths and limitations of approaches directed at correcting the genetic defect through dystrophin gene replacement, modification, repair, and/or a range of dystrophin-independent approaches. The final section highlights the different therapeutic strategies for DMD currently in clinical trials.

Schlagwörter

Stichwörter der Autor:innen

Duchenne muscular dystrophydystrophinmuscle diseasepathophysiologyskeletal muscletherapeutic strategies

Autor:innen und Institutionen

  • Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, MN, United States.

Förderung

  • NIAMS NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023). Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Frontiers in Physiology, 14. https://doi.org/10.3389/fphys.2023.1183101

Vancouver

Bez Batti Angulski A, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Frontiers in Physiology. 2023;14. doi:10.3389/fphys.2023.1183101

BibTeX
@article{BezBattiAngulski2023,
  author = {Bez Batti Angulski, Addeli and Hosny, Nora and Cohen, Houda and Martin, Ashley A and Hahn, Dongwoo and Bauer, Jack and Metzger, Joseph M},
  title = {Duchenne muscular dystrophy: disease mechanism and therapeutic strategies},
  journal = {Frontiers in Physiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphys.2023.1183101}
}
Kostenlos starten →